ES2132432T3 - Compuestos de azetidinona hidroxi-sustituidos utiles como agentes hipocolesterolemicos. - Google Patents
Compuestos de azetidinona hidroxi-sustituidos utiles como agentes hipocolesterolemicos.Info
- Publication number
- ES2132432T3 ES2132432T3 ES94928563T ES94928563T ES2132432T3 ES 2132432 T3 ES2132432 T3 ES 2132432T3 ES 94928563 T ES94928563 T ES 94928563T ES 94928563 T ES94928563 T ES 94928563T ES 2132432 T3 ES2132432 T3 ES 2132432T3
- Authority
- ES
- Spain
- Prior art keywords
- sup
- sub
- aryl
- substituted
- coor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003529 anticholesteremic agent Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Dental Preparations (AREA)
- Pyrrole Compounds (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE PRESENTAN AGENTES HIPOCOLESTEROLEMICOS DE AZETIDINONAS SUSTITUIDAS CON HIDROXI DE LA FORMULA (IA) O DE UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LAS MISMAS, EN LA QUE: AR{SUP,1} Y AR{SUP,2} SON ARILO O ARILO SUSTITUIDO CON R{SUP,4}; AR{SUP,3} ES ARILO O ARILO SUSTITUIDO CON R{SUP,5}; X, Y Y Z SON CH{SUB,2}-, -CH(ALQUILO INFERIOR)- O -C(DIALQUILO INFERIOR)-; R Y R{SUP,2} SON -OR{SUP,6}, -O(CO)R{SUP,6}, -O(CO)OR{SUP,9} O O(CO)NR{SUP,6}R{SUP,7}; R{SUP,1} Y R{SUP,2} SON H O ALQUILO INFERIOR; Q ES 0 O 1; R ES 0 O 1; M, N Y P SON DE 0 A 4; CON LA CONDICION DE QUE AL MENOS UNO DE ENTRE Q Y R SEA 1, Y LA SUMA DE M, N, P, Q Y R SEA DE 1 A 6; Y CON LA CONDICION DE QUE CUANDO P SEA 0 Y R SEA 1, LA SUMA DE M, Q Y N SEA DE 1 A 5; R{SUP,4} SE SELECCIONA DEL ALQUILO INFERIOR, R{SUP,5}, -CF{SUB,3}, -CN, NO{SUB,2} Y HALOGENO; R{SUP,5} SE SELECCIONA DEL -OR{SUP,6}, O(CO)R{SUP,6}, -O(CO)OR{SUP,9}, -O(CH{SUB,2}){SUB,1-5}OR{SUP,6}, -O(CO)NR{SUP,6}R{SUP,7}, -NR{SUP,6}R{SUP,7}, NR{SUP,6}(CO)R{SUP,7}, -NR{SUP,6}(CO)OR{SUP,9}, NR{SUP,6}(CO)NR{SUP,7}R{SUP,8}, -NR{SUP,6}SO{SUB,2}R{SUP,9}, COOR{SUP,6}, -CONR{SUP,6}R{SUP,7}, -COR{SUP,6}, SO{SUB,2}NR{SUP,6}R{SUP,7}, S(O){SUB,0-2}R{SUP,9}, O(CH{SUB,2}){SUB,1-10}-COOR{SUP,6}, -O(CH{SUB,2}){SUB,110}CONR{SUP,6}R{SUP,7}, -(ALQUILENO INFERIOR)COOR{SUP,6} Y CH=CH-COOR{SUP,6}; R{SUP,6}, R{SUP,7} Y R{SUP,8} SON H, ALQUILO INFERIOR, ARILO O ALQUILO INFERIOR SUSTITUIDO CON ARILO; R{SUP,9} ES ALQUILO INFERIOR, ARILO O ALQUILO INFERIOR SUSTITUIDO CON ARILO; ASI COMO UN METODO PARA REDUCIR EL COLESTEROL DEL SUERO MEDIANTE LA ADMINISTRACION DE DICHOS COMPUESTOS, POR SI SOLOS O EN COMBINACION CON UN INHIBIDOR DE LA BIOSINTESIS DEL COLESTEROL, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y UN PROCESO PARA LA PREPARACION DE LOS MISMOS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10244093A | 1993-09-21 | 1993-09-21 | |
| US08/257,593 US5631365A (en) | 1993-09-21 | 1994-06-09 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2132432T3 true ES2132432T3 (es) | 1999-08-16 |
Family
ID=26799377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES94928563T Expired - Lifetime ES2132432T3 (es) | 1993-09-21 | 1994-09-14 | Compuestos de azetidinona hidroxi-sustituidos utiles como agentes hipocolesterolemicos. |
Country Status (35)
| Country | Link |
|---|---|
| US (5) | US5631365A (es) |
| EP (1) | EP0720599B1 (es) |
| JP (1) | JP2803908B2 (es) |
| KR (1) | KR100186853B1 (es) |
| CN (1) | CN1050830C (es) |
| AT (1) | ATE180249T1 (es) |
| AU (1) | AU681445C (es) |
| BE (1) | BE2014C056I2 (es) |
| BR (1) | BR1100159A (es) |
| CA (1) | CA2172149C (es) |
| CZ (2) | CZ288861B6 (es) |
| DE (3) | DE10399001I2 (es) |
| DK (1) | DK0720599T3 (es) |
| ES (1) | ES2132432T3 (es) |
| FI (1) | FI110321B (es) |
| FR (1) | FR05C0040I2 (es) |
| GE (1) | GEP20043149B (es) |
| GR (1) | GR3030312T3 (es) |
| HU (1) | HU221185B1 (es) |
| IL (1) | IL110956A (es) |
| LU (4) | LU91050I2 (es) |
| MA (1) | MA23332A1 (es) |
| MY (1) | MY111314A (es) |
| NL (2) | NL300132I2 (es) |
| NO (6) | NO305902B1 (es) |
| NZ (1) | NZ274041A (es) |
| PL (1) | PL182617B1 (es) |
| RU (1) | RU2138480C1 (es) |
| SG (1) | SG46208A1 (es) |
| SK (1) | SK281067B6 (es) |
| TN (1) | TNSN94094A1 (es) |
| TW (1) | TW427974B (es) |
| UA (1) | UA41948C2 (es) |
| WO (1) | WO1995008532A1 (es) |
| ZA (1) | ZA947086B (es) |
Families Citing this family (244)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5688785A (en) * | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| JPH10501811A (ja) * | 1994-06-20 | 1998-02-17 | シェーリング コーポレイション | 低コレステロール化剤として有用な置換アゼチジノン化合物 |
| US6268392B1 (en) | 1994-09-13 | 2001-07-31 | G. D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
| US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
| US5633246A (en) * | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5624920A (en) * | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5656624A (en) * | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
| CA2231808C (en) * | 1995-09-27 | 2007-05-22 | Schering Corporation | Stereoselective microbial reduction process |
| EP0766962A3 (en) * | 1995-10-03 | 2000-05-10 | Beiersdorf-Lilly GmbH | Treatment of atherosclerosis |
| US5843938A (en) * | 1995-10-03 | 1998-12-01 | Beiersdorf-Lilly Gmbh | Treatment of atherosclerosis |
| CZ293957B6 (cs) * | 1995-10-31 | 2004-08-18 | Scheringácorporation | @@Azetidinony substituované cukernými zbytkyŹ použitelné jako hypocholesterolemikaŹ farmaceutický prostředek a kit je obsahující |
| WO1997016424A1 (en) * | 1995-11-02 | 1997-05-09 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone |
| JP4212112B2 (ja) * | 1996-02-23 | 2009-01-21 | イーライ・リリー・アンド・カンパニー | 非ペプチジルバソプレッシンＶ１ａアンタゴニスト |
| US5739321A (en) * | 1996-05-31 | 1998-04-14 | Schering Corporation | 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones |
| US5886171A (en) * | 1996-05-31 | 1999-03-23 | Schering Corporation | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones |
| US5756470A (en) * | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| FR2762336B1 (fr) * | 1997-04-21 | 1999-06-11 | Francois Trantoul | Procede de fabrication d'un film a motif non reproductible par lecture optique pour la protection de documents |
| US6133001A (en) * | 1998-02-23 | 2000-10-17 | Schering Corporation | Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone |
| US5919672A (en) * | 1998-10-02 | 1999-07-06 | Schering Corporation | Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone |
| US6207822B1 (en) | 1998-12-07 | 2001-03-27 | Schering Corporation | Process for the synthesis of azetidinones |
| JP3640888B2 (ja) * | 1998-12-07 | 2005-04-20 | シェーリング コーポレイション | アゼチジノンの合成プロセス |
| ATE241386T1 (de) * | 1998-12-23 | 2003-06-15 | Searle Llc | Kombinationen von ileumgallensäuretransports inhibitoren und cholesteryl ester transfer protein inhibitoren |
| WO2000038722A1 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS |
| ATE242008T1 (de) | 1998-12-23 | 2003-06-15 | Searle Llc | Kombnationen von cholesteryl ester transfer protein inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen |
| NZ512534A (en) | 1998-12-23 | 2003-11-28 | G | Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications |
| MXPA01006472A (es) | 1998-12-23 | 2004-03-10 | Searle Llc | Combinaciones de inhibidores de transporte de acido biliar ileal y derivados de acido fibrico para indicaciones cardiovasculares. |
| WO2000038721A1 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle Llc | Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications |
| WO2000038725A1 (en) * | 1998-12-23 | 2000-07-06 | G.D. Searle Llc | Combinations for cardiovascular indications |
| JP2002533414A (ja) * | 1998-12-23 | 2002-10-08 | ジー．ディー．サール エルエルシー | 心臓血管に適用するための回腸胆汁酸輸送阻害剤および胆汁酸隔離剤の組み合わせ |
| JP3679715B2 (ja) | 1999-04-05 | 2005-08-03 | シェーリング コーポレイション | １−（４−フルオロフェニル）−３（ｒ）−［３（ｓ）−ヒドロキシ−３−（４−フルオロフェニル）プロピル）］−４（ｓ）−（４−ヒドロキシフェニル）−２−アゼチジノンの調製のための立体選択的微生物還元 |
| US6297268B1 (en) | 1999-11-30 | 2001-10-02 | Schering Corporation | Imidazoles as cholesterol lowering agents |
| AU2001247331A1 (en) * | 2000-03-10 | 2001-09-24 | Pharmacia Corporation | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
| US6794544B2 (en) | 2000-03-10 | 2004-09-21 | Pharmacia Corporation | Method for the preparation of tetrahydrobenzothiepines |
| US6584357B1 (en) * | 2000-10-17 | 2003-06-24 | Sony Corporation | Method and system for forming an acoustic signal from neural timing difference data |
| AU2002227240A1 (en) * | 2000-10-30 | 2002-05-15 | Schering Corporation | Treatment and method using loratadine and montelukast |
| US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| EP1510521A1 (en) * | 2000-12-20 | 2005-03-02 | Schering Corporation | Sugar-substituted 2-Azetidinones useful as hypocholesterolemic agents |
| EP1593670B1 (en) * | 2000-12-20 | 2007-08-08 | Schering Corporation | Hydroxy-substituted 2-azetidinones useful as hypocholesterolemic agents |
| NZ525722A (en) * | 2000-12-20 | 2004-11-26 | Schering Corp | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| IL156552A0 (en) * | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
| JP4605990B2 (ja) * | 2000-12-21 | 2011-01-05 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 新規な１，２−ジフェニルアゼチジノン、その調製方法、その化合物を含む薬剤、および脂質代謝障害を治療するためのその使用 |
| US7071181B2 (en) * | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| AU2008201609B8 (en) * | 2001-01-26 | 2009-01-08 | Organon Llc | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications |
| EP1911462A3 (en) | 2001-01-26 | 2011-11-30 | Schering Corporation | Compositions comprising a sterol absorption inhibitor |
| AR034204A1 (es) * | 2001-01-26 | 2004-02-04 | Schering Corp | Composiciones y combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y el uso de los mismos para preparar medicamentos para el tratamiento para indicaciones vasculares |
| AR033855A1 (es) * | 2001-01-26 | 2004-01-07 | Schering Corp | Composiciones y combinaciones de activador(es) del receptor de activacion de proliferacion peroxis0mal (ppar) e inhibidor(es) de absorcion de esterol, el uso de dichas composiciones o combinaciones para la manufactura de un medicamento para el tratamiento para indicaciones vasculares, diabetes, obes |
| AR032643A1 (es) * | 2001-01-26 | 2003-11-19 | Schering Corp | Combinaciones de inhibidor(es) de absorcion de esterol con agente(s) cardiovascular(es) para el tratamiento de condiciones vasculares |
| AU2007201970B2 (en) * | 2001-01-26 | 2008-04-17 | Organon Llc | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| KR20080067717A (ko) * | 2001-01-26 | 2008-07-21 | 쉐링 코포레이션 | 스테롤 흡수 억제제와 혈액 조절제를 포함하는 혈관 질환의치료 또는 예방용 약제학적 조성물 |
| AU2006203175B2 (en) * | 2001-01-26 | 2008-07-24 | Organon Llc | Combinations of peroxisome proliferator-activated receptor (PPAR) activators(s) and sterol absorption inhibitors(s) and treatments for vascular indications |
| AR035739A1 (es) * | 2001-01-26 | 2004-07-07 | Schering Corp | Composiciones farmaceuticas y combinaciones terapeuticas que comprenden secuestrante (s) de los acidos biliares y de inhibidor (es) de la absorcion de los esteroles y el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento de indicaciones vasculares |
| AU2005246926B2 (en) * | 2001-01-26 | 2008-02-28 | Merck Sharp & Dohme Corp. | The use of substituted azetidinone compounds for the treatment of sitosterolemia |
| AU2006202618B2 (en) * | 2001-01-26 | 2007-04-19 | Organon Llc | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| SK287746B6 (sk) * | 2001-01-26 | 2011-08-04 | Schering Corporation | Použitie substituovaných azetidinónových zlúčenín na liečenie sitosterolémie |
| TWI291957B (en) * | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
| CZ304929B6 (cs) * | 2001-03-28 | 2015-01-28 | Merck Sharp & Dohme Corp. | Enantioselektivní syntéza azetidinonových meziproduktů |
| PT1392287E (pt) * | 2001-05-25 | 2007-02-28 | Schering Corp | Métodos para tratamento de doença de alzheimer e/ou regulação dos níveis de peptídeos β amilóide num sujeito |
| US20040077625A1 (en) * | 2001-07-25 | 2004-04-22 | Tremont Samuel J. | Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake |
| EP1859796A3 (en) * | 2001-09-21 | 2008-07-02 | Schering Corporation | Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| US20030119808A1 (en) * | 2001-09-21 | 2003-06-26 | Schering Corporation | Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects |
| DK1429756T3 (da) * | 2001-09-21 | 2007-03-19 | Schering Corp | Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer |
| US7053080B2 (en) * | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| WO2003040127A1 (en) * | 2001-11-02 | 2003-05-15 | G.D. Searle Llc | Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake |
| IL161741A0 (en) * | 2001-11-09 | 2005-11-20 | Atherogenics Inc | Methods of reversing and preventingcardiovascular pathologies |
| US7202247B2 (en) | 2001-12-19 | 2007-04-10 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders |
| IL162533A0 (en) * | 2001-12-19 | 2005-11-20 | Atherogenics Inc | Chalcone derivatives and their use to treat diseases |
| FR2833842B1 (fr) * | 2001-12-21 | 2004-02-13 | Aventis Pharma Sa | Compositions pharmaceutiques a base de derives d'azetidine |
| BR0306643A (pt) | 2002-01-17 | 2004-10-19 | Pharmacia Corp | Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical |
| EP1480689A1 (en) * | 2002-02-28 | 2004-12-01 | Eli Lilly And Company | Method of treating atherosclerosis and hypercholesterolemia |
| US20040116510A1 (en) * | 2002-03-05 | 2004-06-17 | Nichtberger Steven A. | Antihypertensive agent and cholesterol absorption inhibitor combination therapy |
| US20030204096A1 (en) * | 2002-03-25 | 2003-10-30 | Schering Corporation | Enantioselective synthesis of azetidinone intermediate compounds |
| DE10227508A1 (de) * | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| GB0215579D0 (en) * | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| PL374860A1 (en) | 2002-07-09 | 2005-11-14 | Bristol-Myers Squibb Company | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| US20040132058A1 (en) | 2002-07-19 | 2004-07-08 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
| US7135556B2 (en) * | 2002-07-19 | 2006-11-14 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
| AR040588A1 (es) * | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
| NZ538498A (en) * | 2002-07-30 | 2009-02-28 | Childrens Medical Center | Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors |
| AU2003303239A1 (en) * | 2002-12-19 | 2004-07-14 | Atherogenics, Inc. | Process of making chalcone derivatives |
| ES2318274T3 (es) * | 2003-03-07 | 2009-05-01 | Schering Corporation | Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia. |
| JP5137228B2 (ja) * | 2003-03-07 | 2013-02-06 | メルク・シャープ・アンド・ドーム・コーポレーション | 高コレステロール血症の処置のための置換アゼチジノン化合物、置換アゼチジノン処方物およびそれらの使用 |
| MXPA05009502A (es) * | 2003-03-07 | 2005-10-18 | Schering Corp | Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. |
| WO2004099132A2 (en) * | 2003-05-05 | 2004-11-18 | Ranbaxy Laboratories Limited | Process for the preparation of trans-isomers of diphenylazetidinone derivatives |
| AR041089A1 (es) | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
| NZ543741A (en) * | 2003-05-30 | 2009-10-30 | Ranbaxy Lab Ltd | Substituted pyrrole derivatives and their use as HMG-Co inhibitors |
| US20060148721A1 (en) * | 2003-06-06 | 2006-07-06 | Erondu Ngozi E | Combination therapy for the treatment of dyslipidemia |
| EP1651231A4 (en) * | 2003-07-24 | 2009-04-01 | Merck & Co Inc | CYCLOALKANES DIPHENYL-SUBSTITUTES, COMPOSITIONS CONTAINING THESE COMPOUNDS, AND METHODS OF USE |
| WO2005009955A1 (en) * | 2003-07-31 | 2005-02-03 | Hetero Drugs Limited | Ezetimibe polymorphs |
| EP1522541A1 (en) * | 2003-10-07 | 2005-04-13 | Lipideon Biotechnology AG | Novel hypocholesterolemic compounds |
| WO2005042692A2 (en) * | 2003-10-31 | 2005-05-12 | Forbes Medi-Tech Inc. | A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors |
| EP1918000A2 (en) | 2003-11-05 | 2008-05-07 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
| US20050096307A1 (en) * | 2003-11-05 | 2005-05-05 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
| NZ546940A (en) * | 2003-11-10 | 2008-11-28 | Microbia Inc | 4-Biarylyl-1-phenylazetidin-2-ones |
| US7067675B2 (en) * | 2003-11-24 | 2006-06-27 | Hetero Drugs Limited | Process for ezetimibe intermediate |
| JP2007516287A (ja) | 2003-12-23 | 2007-06-21 | メルク エンド カムパニー インコーポレーテッド | 抗高コレステロール血症化合物 |
| GB0329778D0 (en) * | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
| WO2005061452A1 (en) * | 2003-12-23 | 2005-07-07 | Astrazeneca Ab | Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
| EP1723414A4 (en) * | 2004-01-16 | 2008-03-26 | Merck & Co Inc | NPC1L1 (NPC3) AND METHOD FOR IDENTIFYING ITS LIGANDS |
| SI1725234T1 (sl) | 2004-03-05 | 2013-04-30 | The Trustees Of The University Of Pennsylvania | Postopki zdravljenja nepravilnosti ali bolezni povezanih s hiperlipidemijo in hiperholesterolemijo z minimiziranjem stranskih uäśinkov |
| US20060211752A1 (en) | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
| US20050244367A1 (en) * | 2004-05-03 | 2005-11-03 | Ilypsa, Inc. | Phospholipase inhibitors localized in the gastrointestinal lumen |
| KR20070027554A (ko) * | 2004-05-21 | 2007-03-09 | 사노피-아벤티스 도이칠란트 게엠베하 | 1,4-디페닐 아제티딘온 유도체의 제조방법 |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| US20060063828A1 (en) * | 2004-06-28 | 2006-03-23 | Weingarten M D | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof |
| US20070244107A1 (en) * | 2004-08-25 | 2007-10-18 | Waters M Gerard | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions |
| US20060046996A1 (en) | 2004-08-31 | 2006-03-02 | Kowa Co., Ltd. | Method for treating hyperlipidemia |
| AR050631A1 (es) * | 2004-09-09 | 2006-11-08 | Novartis Ag | Combinacion de compuestos organicos |
| MX2007003732A (es) * | 2004-09-29 | 2007-04-23 | Schering Corp | Combinaciones de azetidononas sustituidas y antagonistas de receptor de canabinoide 1. |
| KR101351209B1 (ko) | 2004-12-03 | 2014-02-06 | 머크 샤프 앤드 돔 코포레이션 | Ｃｂ1 길항제로서 치환된 피페라진 |
| EP1834180A2 (en) * | 2004-12-15 | 2007-09-19 | Schering Corporation | Functional assays for cholesterol absorption inhibitors |
| US20130082232A1 (en) | 2011-09-30 | 2013-04-04 | Unity Semiconductor Corporation | Multi Layered Conductive Metal Oxide Structures And Methods For Facilitating Enhanced Performance Characteristics Of Two Terminal Memory Cells |
| BRPI0609614A2 (pt) | 2005-04-04 | 2010-04-20 | Univ Pontificia Catolica Chile | uso de ezetimiba na prevenção e tratamento de litìases de colesterol na árvore biliar |
| TW200726746A (en) | 2005-05-06 | 2007-07-16 | Microbia Inc | Processes for production of 4-biphenylylazetidin-2-ones |
| AU2006244125A1 (en) * | 2005-05-09 | 2006-11-16 | Microbia, Inc. | Organometal benzenephosphonate coupling agents |
| JP2008540557A (ja) * | 2005-05-11 | 2008-11-20 | マイクロビア インコーポレーテッド | フェノール型４−ビフェニリルアゼチジン−２−オンの製造方法 |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| AU2006249905A1 (en) * | 2005-05-25 | 2006-11-30 | Microbia, Inc. | Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids |
| JP2008543837A (ja) * | 2005-06-15 | 2008-12-04 | メルク エンド カムパニー インコーポレーテッド | 抗高コレステロール血症化合物 |
| CA2610959A1 (en) * | 2005-06-20 | 2007-01-04 | Schering Corporation | Piperidine derivatives useful as histamine h3 antagonists |
| SA06270191B1 (ar) * | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
| AR054482A1 (es) * | 2005-06-22 | 2007-06-27 | Astrazeneca Ab | Derivados de azetidinona para el tratamiento de hiperlipidemias |
| CA2613239A1 (en) * | 2005-06-22 | 2006-12-28 | Manne Satyanarayana Reddy | Improved process for the preparation of ezetimibe |
| EP1741427A1 (en) * | 2005-07-06 | 2007-01-10 | KRKA, D.D., Novo Mesto | Pharmaceutical composition comprising simvastatin and ezetimibe |
| US20070049748A1 (en) * | 2005-08-26 | 2007-03-01 | Uppala Venkata Bhaskara R | Preparation of ezetimibe |
| CA2616058A1 (en) * | 2005-09-08 | 2007-03-15 | Vinod Kumar Kansal | Processes for the preparation of (3r,4s)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((s)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe |
| TW200806623A (en) * | 2005-10-05 | 2008-02-01 | Merck & Co Inc | Anti-hypercholesterolemic compounds |
| JP2009512715A (ja) | 2005-10-21 | 2009-03-26 | ノバルティス アクチエンゲゼルシャフト | レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ |
| JP2009514851A (ja) * | 2005-11-08 | 2009-04-09 | ランバクシー ラボラトリーズ リミテッド | （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法 |
| HU0501164D0 (en) * | 2005-12-20 | 2006-02-28 | Richter Gedeon Vegyeszet | New industrial process for the production of ezetimibe |
| JP2009521452A (ja) * | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | コレステロール降下剤およびｈ３受容体アンタゴニスト／逆アゴニストを使用する非アルコール性脂肪性肝疾患の処置 |
| DE602006009845D1 (de) * | 2005-12-22 | 2009-11-26 | Medichem Sa | Verfahren zur herstellung von zwischenprodukten für die herstellung von ezetimibe |
| US7897601B2 (en) | 2006-01-18 | 2011-03-01 | Intervet, Inc. | Cannabinoid receptor modulators |
| WO2007094480A1 (ja) * | 2006-02-16 | 2007-08-23 | Kotobuki Pharmaceutical Co., Ltd. | 光学活性アルコールを製造する方法 |
| US7910698B2 (en) * | 2006-02-24 | 2011-03-22 | Schering Corporation | NPC1L1 orthologues |
| KR20080096851A (ko) * | 2006-03-06 | 2008-11-03 | 테바 파마슈티컬 인더스트리즈 리미티드 | 에제티미베 조성물 |
| AR059838A1 (es) * | 2006-03-14 | 2008-04-30 | Ranbaxy Lab Ltd | Formulaciones para dosis estabilizantes de estatina |
| WO2007120824A2 (en) * | 2006-04-10 | 2007-10-25 | Teva Pharmaceutical Industries Ltd. | Processes for the synthesis of azetidinone |
| AR060623A1 (es) * | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
| US20070275052A1 (en) * | 2006-05-24 | 2007-11-29 | Glenmark Pharmaceuticals Limited | Pharmaceutical compositions containing sterol inhibitors |
| JP2009543773A (ja) * | 2006-07-14 | 2009-12-10 | ランバクシー ラボラトリーズ リミテッド | ＨＭＧ−ＣｏＡレダクターゼ阻害剤の多形体及びその使用 |
| BRPI0706041A2 (pt) * | 2006-08-29 | 2011-03-22 | Teva Pharmaceutichal Ind Ltd | processos para purificação de (3r,4s)-4-(fenil-4-hydroxi-protegido)-1-(4-fluorofenil)- 3-[3-(4-fluorofenil)-3-oxoprofil]azetidina-2-ona |
| MX2009002398A (es) * | 2006-09-05 | 2009-03-16 | Schering Corp | Combinaciones farmaceuticas para manejo de lipidos y en el tratamiento de aterosclerosis y estatosis hepatica. |
| MX2009002924A (es) * | 2006-09-15 | 2009-05-28 | Schering Corp | Derivados de azetidinona espirociclica para el tratamiento de trastornos del metabolismo de los lipidos, el dolor, la diabetes y otros trastornos. |
| CA2663500A1 (en) * | 2006-09-15 | 2008-03-20 | Schering Corporation | Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism |
| CN101541805A (zh) | 2006-09-15 | 2009-09-23 | 先灵公司 | 用于治疗疼痛和脂代射紊乱的氮杂环丁烷和氮杂环丁酮衍生物 |
| JP2010503677A (ja) * | 2006-09-15 | 2010-02-04 | シェーリング コーポレイション | 脂質代謝の障害を治療するためのアゼチジノン誘導体 |
| MX2009002918A (es) * | 2006-09-15 | 2009-03-31 | Schering Corp | Derivados azetidinona y sus metodos de uso. |
| US20080085315A1 (en) * | 2006-10-10 | 2008-04-10 | John Alfred Doney | Amorphous ezetimibe and the production thereof |
| CN100564357C (zh) * | 2006-10-20 | 2009-12-02 | 浙江天宇药业有限公司 | 一种氮杂环丁酮衍生物及其合成方法 |
| CA2672221A1 (en) * | 2006-12-20 | 2008-07-17 | Merck & Co., Inc. | Anti-hypercholesterolemic compounds |
| US20080161279A1 (en) * | 2006-12-21 | 2008-07-03 | Wisler Gerald L | Methods of Treating Obesity |
| EP1939174A1 (en) * | 2006-12-21 | 2008-07-02 | LEK Pharmaceuticals D.D. | Inclusion complex of ezetimibe and a cyclodextrin and processes in the preparation thereof |
| EP2125715A2 (en) * | 2007-01-24 | 2009-12-02 | Krka | Process for the preparation of ezetimibe and derivatives thereof |
| WO2008096372A2 (en) * | 2007-02-06 | 2008-08-14 | Ind-Swift Laboratories Limited | Process for preparing highly pure ezetimibe using novel intermediates |
| WO2008104875A1 (en) * | 2007-03-01 | 2008-09-04 | Pfizer Products Inc. | Oxazolidinones as cholesterol absorption inhibitors |
| JPWO2008108486A1 (ja) | 2007-03-06 | 2010-06-17 | 帝人ファーマ株式会社 | １−ビアリールアゼチジノン誘導体 |
| EP2134169A2 (en) | 2007-03-09 | 2009-12-23 | Indigene Pharmaceuticals Inc. | Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications |
| WO2008123953A1 (en) * | 2007-04-02 | 2008-10-16 | Merck & Co., Inc. | Anti-hypercholesterolemic compound |
| WO2008130616A2 (en) * | 2007-04-19 | 2008-10-30 | Schering Corporation | Diaryl morpholines as cb1 modulators |
| US8048880B2 (en) * | 2007-05-03 | 2011-11-01 | Anthera Pharmaceuticals, Inc. | Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies |
| US20090047716A1 (en) * | 2007-06-07 | 2009-02-19 | Nurit Perlman | Reduction processes for the preparation of ezetimibe |
| US20080318920A1 (en) * | 2007-06-19 | 2008-12-25 | Protia, Llc | Deuterium-enriched ezetimibe |
| US20080319218A1 (en) * | 2007-06-22 | 2008-12-25 | Andreas Haubrich | Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate |
| US20080319221A1 (en) * | 2007-06-22 | 2008-12-25 | Bernd Junker | Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids |
| CN101790521A (zh) * | 2007-06-28 | 2010-07-28 | 英特维特国际股份有限公司 | 作为cb1拮抗剂的取代哌嗪 |
| CA2692268A1 (en) * | 2007-06-28 | 2009-01-08 | Intervet International B.V. | Substituted piperazines as cb1 antagonists |
| KR20100051667A (ko) * | 2007-07-27 | 2010-05-17 | 씨아이피엘에이 엘티디. | 약제학적 조성물 및 그의 제조방법 |
| WO2009024889A2 (en) | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe |
| WO2009032264A1 (en) * | 2007-08-30 | 2009-03-12 | Teva Pharmaceutical Industries Ltd. | Processes for preparing intermediates of ezetimibe by microbial reduction |
| WO2009027785A2 (en) * | 2007-08-30 | 2009-03-05 | Pfizer Products Inc. | 1, 3-oxazole derivatives as cetp inhibitors |
| DE102007063671A1 (de) * | 2007-11-13 | 2009-06-25 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| EP2965752A1 (en) | 2007-12-10 | 2016-01-13 | ratiopharm GmbH | Pharmaceutical formulation comprising ezetimibe |
| CZ305066B6 (cs) * | 2008-02-25 | 2015-04-22 | Zentiva, K.S. | Způsob výroby (3R,4S)-1-(4-fluorfenyl)-3-[(3S)-3-(4-fluorfenyl)-3-hydroxypropyl)]-4-(4-hydroxyfenyl)-2-azetidinonu |
| EP2128133A1 (en) | 2008-05-26 | 2009-12-02 | Lek Pharmaceuticals D.D. | Ezetimibe process and composition |
| EP2307053A2 (en) * | 2008-06-06 | 2011-04-13 | Nicox S.A. | Compositions comprising atorvastatin 4-(nitrooxy) butyl ester and a hypolipidemic drug |
| US20090312302A1 (en) * | 2008-06-17 | 2009-12-17 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders |
| SG10201404330VA (en) | 2008-08-29 | 2014-10-30 | Codexis Inc | Ketoreductase Polypeptides For The Stereoselective Production Of (4S)-3[(5S)-5(4-Fluorophenyl)-5-Hydroxypentanoyl]-4-Phenyl-1,3-Oxazolidin-2-One |
| JP2012508791A (ja) | 2008-11-14 | 2012-04-12 | フラムローゼ，ボミ，ピー． | アテローム性動脈硬化症の治療のための循環酸化低密度リポタンパク質‐ベータ‐２‐糖タンパク質１複合体を減少させる方法 |
| EP2204170A1 (en) | 2008-12-01 | 2010-07-07 | LEK Pharmaceuticals D.D. | Pharmaceutical composition comprising ezetimibe and simvastatin |
| US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
| US20110245209A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
| EP2216016A1 (en) | 2009-02-06 | 2010-08-11 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising ezetimibe |
| CA2754384A1 (en) | 2009-03-06 | 2010-09-10 | Lipideon Biotechnology Ag | Pharmaceutical hypocholesterolemic compositions |
| ATE536172T1 (de) | 2009-03-13 | 2011-12-15 | Sanovel Ilac Sanayi Ve Ticaret As | Ezetimibzusammensetzungen |
| EP2414326B1 (en) | 2009-03-31 | 2017-12-20 | Lupin Limited | Intermediates in the preparation of 1,4-diphenyl azetidinone |
| WO2010113175A2 (en) | 2009-04-01 | 2010-10-07 | Matrix Laboratories Ltd | Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe |
| WO2011002424A2 (en) | 2009-07-02 | 2011-01-06 | Bilgic Mahmut | Solubility and stability enchancing pharmaceutical formulation |
| WO2011019326A2 (en) | 2009-07-02 | 2011-02-17 | Mahmut Bilgic | Solubility and stability enchancing pharmaceutical formulation |
| WO2011002422A2 (en) | 2009-07-02 | 2011-01-06 | Bilgic Mahmut | Solubility enhancing pharmaceutical formulation |
| CN101993403B (zh) | 2009-08-11 | 2012-07-11 | 浙江海正药业股份有限公司 | 氮杂环丁酮类化合物及医药应用 |
| EP2467473B1 (en) | 2009-08-19 | 2016-03-23 | Codexis, Inc. | Ketoreductase polypeptides for the preparation of phenylephrine |
| CA2790999C (en) | 2010-02-24 | 2019-05-14 | Relypsa, Inc. | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants |
| BR112012021448A2 (pt) | 2010-02-24 | 2016-05-31 | Relypsa Inc | polímero de amina, método para tratar doença, método de remoção de sais biliares de um indivíduo animal, método para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de amina. |
| KR101822608B1 (ko) | 2010-02-24 | 2018-01-29 | 리립사, 인크. | 담즙산 격리제로서 사용하기 위한 아민 폴리머 |
| EP2368543A1 (en) | 2010-03-25 | 2011-09-28 | KRKA, tovarna zdravil, d.d., Novo mesto | Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe |
| MX338426B (es) | 2010-04-23 | 2016-04-15 | Synageva Biopharma Corp | Enzima de enfermedad del almacenamiento lisosomico. |
| US9040262B2 (en) | 2010-05-04 | 2015-05-26 | Codexis, Inc. | Biocatalysts for ezetimibe synthesis |
| ES2372460B1 (es) | 2010-07-09 | 2012-11-16 | Moehs Ibérica S.L. | Nuevo método para la preparación de ezetimiba. |
| NZ700824A (en) | 2010-09-09 | 2016-03-31 | Synageva Biopharma Corp | Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients |
| BR112013010705B1 (pt) | 2010-11-08 | 2020-11-17 | Albireo Ab | uso de um inibidor de ibat e um coagulante de ácido biliar, e formulação farmacêutica |
| KR101890959B1 (ko) | 2010-11-08 | 2018-08-22 | 알비레오 에이비 | 간질환 치료를 위한 ｉｂａｔ 억제제 |
| WO2012076030A1 (en) | 2010-12-10 | 2012-06-14 | Pharmathen S.A. | Process for the preparation of intermediate compounds useful in the preparation of ezetimibe |
| WO2012112681A1 (en) | 2011-02-15 | 2012-08-23 | Shire Human Genetic Therapies, Inc. | Methods for treating lysosomal acid lipase deficiency |
| US8455474B2 (en) | 2011-03-04 | 2013-06-04 | Mackay Memorial Hospital | Method for treating tuberculosis |
| WO2012155932A1 (en) | 2011-05-17 | 2012-11-22 | Pharmathen S.A. | Improved process for the preparation of ezetimibe |
| PL231215B1 (pl) | 2011-06-15 | 2019-02-28 | Inst Chemii Organicznej Polskiej Akademii Nauk | Sposób wytwarzania podstawionych azetydynonów oraz związków pośrednich do ich syntezy |
| CN102675177A (zh) * | 2011-06-28 | 2012-09-19 | 常州制药厂有限公司 | 一种降血脂药物及其关键中间体的制备方法 |
| CN102952055A (zh) * | 2011-08-16 | 2013-03-06 | 凯瑞斯德生化(苏州)有限公司 | 一种依泽替米贝和其中间体的制备方法 |
| CN103204795B (zh) * | 2012-01-11 | 2016-12-14 | 重庆华邦胜凯制药有限公司 | 一种手性氮杂环丁酮类化合物的制备方法 |
| HUE052300T2 (hu) | 2012-05-01 | 2021-04-28 | Althera Life Sciences Llc | Orális tablettakészítmény, amely a rozuvastatin és az ezetimib rögzített kombinációjából áll, hiperlipidémia és kardiovaszkuláris betegségek kezelésére |
| CN103570574B (zh) | 2012-07-20 | 2016-04-13 | 中国科学院上海有机化学研究所 | 一种依泽替米贝的合成方法及该方法中所用的中间体 |
| CN103102297A (zh) * | 2012-09-28 | 2013-05-15 | 北京赛林泰医药技术有限公司 | 一种新的依折麦布的合成方法 |
| TW201427658A (zh) | 2012-12-10 | 2014-07-16 | Merck Sharp & Dohme | 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法 |
| CN103864708A (zh) * | 2012-12-12 | 2014-06-18 | 天津市医药集团技术发展有限公司 | 一种依折麦布中间体的制备方法 |
| WO2015039675A1 (en) | 2013-09-23 | 2015-03-26 | Pharmathen S.A. | Novel process for the preparation of ezetimibe intermediates |
| EP3065736B1 (en) | 2013-11-04 | 2018-11-14 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions thereof, and methods of use |
| WO2015092448A1 (en) | 2013-12-18 | 2015-06-25 | Rudjer Boskovic Institute | Beta-lactam cholesterol absorption inhibitors |
| CN103739537B (zh) * | 2013-12-24 | 2015-05-20 | 连云港恒运医药科技有限公司 | 依折麦布的新合成方法 |
| KR20150079373A (ko) | 2013-12-30 | 2015-07-08 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 |
| CN103755616A (zh) * | 2013-12-31 | 2014-04-30 | 北京万全德众医药生物技术有限公司 | 一种制备依泽替米贝异构体的方法 |
| KR20160147007A (ko) | 2014-05-30 | 2016-12-21 | 화이자 인코포레이티드 | 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체 |
| CN105294426B (zh) * | 2014-06-09 | 2019-05-14 | 浙江海正药业股份有限公司 | 氮杂环丁酮化合物制备方法及其中间体 |
| CN104447474A (zh) * | 2014-11-11 | 2015-03-25 | 武汉武药科技有限公司 | 一种依折麦布异构体的合成方法 |
| CN104387308A (zh) * | 2014-11-18 | 2015-03-04 | 武汉福星生物药业有限公司 | 一种控制EZ-zanOH杂质产生制备高纯度依折麦布的方法 |
| CN104513187B (zh) * | 2015-01-09 | 2017-05-31 | 安润医药科技（苏州）有限公司 | 依折麦布及其中间体的合成方法 |
| JP2016145173A (ja) * | 2015-02-09 | 2016-08-12 | 株式会社トクヤマ | （３ｒ，４ｓ）‐１‐（４‐フルオロフェニル）‐［３（ｓ）‐ヒドロキシ‐３‐（４‐フルオロフェニル）プロピル］‐（４‐ヒドロキシフェニル）‐２‐アゼチジノンの製造方法 |
| AU2016233485B2 (en) | 2015-03-13 | 2021-05-20 | Esperion Therapeutics, Inc. | Fixed dose combinations and formulations comprising ETC1002 and Ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
| MA41793A (fr) | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
| CN105287513A (zh) * | 2015-10-23 | 2016-02-03 | 浙江永宁药业股份有限公司 | 一种依折麦布药物组合物及其制备方法 |
| CN107098841A (zh) * | 2016-02-19 | 2017-08-29 | 常州方楠医药技术有限公司 | 一种依折麦布的制备方法及该方法中所用的中间体 |
| JP6883664B2 (ja) | 2016-12-05 | 2021-06-09 | パットスナップ リミテッド | 大規模データベース内で論じられる化学構造の類似性に従って大規模データベースで利用可能な情報を検索及び表示するためのシステム |
| US20180338922A1 (en) | 2017-05-26 | 2018-11-29 | Esperion Therapeutics, Inc. | Fixed dose formulations |
| EP3437636A1 (en) | 2017-08-02 | 2019-02-06 | Adamed sp. z o.o. | Pharmaceutical composition comprising ezetimibe |
| US11408274B2 (en) | 2018-01-16 | 2022-08-09 | Q.E.D. Environmental Systems, Inc. | Fluid level monitoring system and method incorporating pressure sensor system having inflatable/collapsible bag |
| US11331332B2 (en) | 2019-03-20 | 2022-05-17 | Regeneron Pharmaceuticals, Inc. | Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (SCAP) inhibitors |
| CN116889627A (zh) | 2019-03-20 | 2023-10-17 | 雷杰纳荣制药公司 | 用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高 |
| WO2021019499A1 (en) | 2019-07-31 | 2021-02-04 | TECNIMEDE - Sociedade Técnico-medicinal, SA | Solid oral multiple-unit immediate release compositions, methods and uses thereof |
| EP4188338A1 (en) | 2020-07-27 | 2023-06-07 | KRKA, d.d., Novo mesto | Bilayer tablet comprising ezetimibe and atorvastatin |
| EP4357333A1 (en) * | 2021-06-17 | 2024-04-24 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Hybutimibe intermediate and preparation method therefor |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
| WO2024151311A1 (en) | 2023-01-09 | 2024-07-18 | Esperion Therapeutics, Inc. | Methods of treatment using bempedoic acid |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2046823A1 (de) | 1970-09-23 | 1972-03-30 | Farbwerke Hoechst AG vormals Meister Lucius & Brüning, 6000 Frankfurt | Neue Azetidinone-(2) und Verfahren zu deren Herstellung |
| CA1063108A (en) | 1973-12-28 | 1979-09-25 | Fujisawa, Pharmaceutical Co. | Azetidinone derivatives and process for preparation thereof |
| US4576753A (en) | 1975-10-06 | 1986-03-18 | Fujisawa Pharmaceutical Co., Ltd. | Azetidinone compounds and processes for preparation thereof |
| US4144232A (en) | 1976-12-23 | 1979-03-13 | Eli Lilly And Company | Substituted azetidin-2-one antibiotics |
| US4375475A (en) * | 1979-08-17 | 1983-03-01 | Merck & Co., Inc. | Substituted pyranone inhibitors of cholesterol synthesis |
| US4500456A (en) | 1981-03-09 | 1985-02-19 | Eli Lilly And Company | Preparation of 4-fluoroazetidinones using FClO3 |
| IL65158A0 (en) | 1981-03-09 | 1982-05-31 | Lilly Co Eli | Azetidinones |
| US4784734A (en) | 1981-04-10 | 1988-11-15 | Otsuka Kagaku Yakuhin Kabushiki Kaisha | Azetidinone derivatives and process for the preparation of the same |
| US4443372A (en) | 1982-06-23 | 1984-04-17 | Chevron Research Company | 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators |
| US4595532A (en) | 1983-02-02 | 1986-06-17 | University Of Notre Dame Du Lac | N-(substituted-methyl)-azetidin-2-ones |
| IL70782A (en) | 1983-02-02 | 1991-03-10 | Univ Notre Dame Du Lac | N-dicarboxymethyl azetidin-2-ones |
| US4565654A (en) | 1983-03-28 | 1986-01-21 | University Of Notre Dame Du Lac | N-Acyloxy monocyclic β-lactams |
| US4675399A (en) | 1983-03-28 | 1987-06-23 | Notre Dame University | Cyclization process for β-lactams |
| WO1985004876A1 (en) | 1984-04-24 | 1985-11-07 | Takeda Chemical Industries, Ltd. | 2-azetidinone derivatives and process for their preparation |
| US4576749A (en) | 1983-10-03 | 1986-03-18 | E. R. Squibb & Sons, Inc. | 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones |
| US5229381A (en) | 1983-12-01 | 1993-07-20 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| US5229510A (en) | 1983-12-01 | 1993-07-20 | Merck & Co., Inc. | β-lactams useful in determining the amount of elastase in a clinical sample |
| US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| JPS61501205A (ja) | 1984-02-15 | 1986-06-19 | シェリング・コ−ポレ−ション | ８↓−クロル↓−６，１１↓−ジヒドロ↓−１１↓−（４↓−ピペリジリデン）↓−５Ｈ↓−ベンゾ〔５，６〕シクロヘプタ〔１，２−ｂ〕ピリジンおよびその塩、これらの化合物の製造方法、ならびにこれらの化合物を含有する医薬組成物 |
| CA1268780A (en) | 1984-08-03 | 1990-05-08 | Richard H. Mueller | N-hydroxyl protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones |
| US4633017A (en) | 1984-08-03 | 1986-12-30 | E. R. Squibb & Sons, Inc. | N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones |
| US4581170A (en) | 1984-08-03 | 1986-04-08 | E. R. Squibb & Sons, Inc. | N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones |
| US4620867A (en) | 1984-09-28 | 1986-11-04 | Chevron Research Company | 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides |
| WO1987004429A1 (en) | 1986-01-23 | 1987-07-30 | The Upjohn Company | Antimicrobial n-acyl-2-azetidinones |
| US4847271A (en) | 1986-01-27 | 1989-07-11 | Merck & Co., Inc. | Antihypercholesterolemic β-lactones |
| USRE36481E (en) | 1986-06-23 | 2000-01-04 | Merck & Co., Inc. | HMG-CoA reductase inhibitors |
| US4803266A (en) * | 1986-10-17 | 1989-02-07 | Taisho Pharmaceutical Co., Ltd. | 3-Oxoalkylidene-2-azetidinone derivatives |
| US4816477A (en) | 1987-05-26 | 1989-03-28 | Merck & Co., Inc. | Antihypercholesterolemic β-lactones |
| US4806564A (en) | 1987-05-26 | 1989-02-21 | Merck & Co., Inc. | Antihypercholesterolemic beta-lactones |
| US4759923A (en) | 1987-06-25 | 1988-07-26 | Hercules Incorporated | Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives |
| US4834846A (en) | 1987-12-07 | 1989-05-30 | Merck & Co., Inc. | Process for deblocking N-substituted β-lactams |
| EP0333268A1 (en) | 1988-03-18 | 1989-09-20 | Merck & Co. Inc. | Process for synthesis of a chiral 3-beta hydrogen (3R) 4-aroyloxy azetidinone |
| NZ228600A (en) * | 1988-04-11 | 1992-02-25 | Merck & Co Inc | 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives |
| JPH0645656B2 (ja) | 1988-06-16 | 1994-06-15 | 出光石油化学株式会社 | スチレン系共重合体およびその製造方法 |
| US4952689A (en) | 1988-10-20 | 1990-08-28 | Taisho Pharmaceutical Co., Ltd. | 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation |
| US4876365A (en) | 1988-12-05 | 1989-10-24 | Schering Corporation | Intermediate compounds for preparing penems and carbapenems |
| FR2640621B1 (fr) | 1988-12-19 | 1992-10-30 | Centre Nat Rech Scient | N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases |
| CA2016467A1 (en) | 1989-06-05 | 1990-12-05 | Martin Eisman | Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor |
| JPH03108490A (ja) * | 1989-06-30 | 1991-05-08 | Shionogi & Co Ltd | フォスフォリパーゼａ↓２阻害物質 |
| US4983597A (en) | 1989-08-31 | 1991-01-08 | Merck & Co., Inc. | Beta-lactams as anticholesterolemic agents |
| US5120729A (en) | 1990-06-20 | 1992-06-09 | Merck & Co., Inc. | Beta-lactams as antihypercholesterolemics |
| IL99658A0 (en) | 1990-10-15 | 1992-08-18 | Merck & Co Inc | Substituted azetidinones and pharmaceutical compositions containing them |
| AU1886892A (en) | 1991-04-12 | 1992-11-17 | Schering Corporation | Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase |
| US5124337A (en) | 1991-05-20 | 1992-06-23 | Schering Corporation | N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase |
| GB2264707A (en) | 1991-06-18 | 1993-09-08 | Roger Michael Marchbanks | Acridine derivatives for treating alzheimer's disease |
| US5348953A (en) | 1991-06-25 | 1994-09-20 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| WO1993000332A1 (en) | 1991-06-25 | 1993-01-07 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| CA2114007C (en) | 1991-07-23 | 2005-12-20 | Duane A. Burnett | Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof |
| JP2525125B2 (ja) | 1991-07-23 | 1996-08-14 | シェリング・コーポレーション | 血清コレステロ―ル低下薬として有用な置換β−ラクタム化合物およびそれらの製法 |
| US5688787A (en) | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof |
| US5688785A (en) | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| JP2620437B2 (ja) * | 1991-09-27 | 1997-06-11 | 宇部興産株式会社 | ω−ヒドロキシ−（ω−３）−ケトニトリルおよびω−ヒドロキシ脂肪酸の製法 |
| US5238950A (en) | 1991-12-17 | 1993-08-24 | Schering Corporation | Inhibitors of platelet-derived growth factor |
| US5321031A (en) | 1992-09-23 | 1994-06-14 | Schering Corporation | 1,2-disubstituted ethyl amides as inhibitors of ACAT |
| US5631363A (en) | 1992-11-13 | 1997-05-20 | Tanabe Seiyaku Co., Ltd. | Azetidinone compound and process for preparation thereof |
| LT3300B (en) | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
| LT3595B (en) | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
| WO1994017036A1 (en) | 1993-01-22 | 1994-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | S-lipophilic aliphatic carbonyl [n-mercaptoacyl-(amino acid or peptide)] compounds as antihypertensive agents |
| AU681875B2 (en) | 1993-02-26 | 1997-09-11 | Schering Corporation | 2-benzyl-polycyclic guanine derivatives and process for preparing them |
| US5412092A (en) | 1993-04-23 | 1995-05-02 | Bristol-Myers Squibb Company | N-substituted 2-azetidinones |
| US5550229A (en) | 1993-06-23 | 1996-08-27 | Tanabe Seiyaku Co., Ltd. | Alkylation process for preparing azetidinone compound and starting compound therefor |
| NZ268798A (en) | 1993-07-09 | 1997-01-29 | Schering Corp | Process for the preparation of substituted azetidinones |
| US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5627176A (en) | 1994-03-25 | 1997-05-06 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| GB9406074D0 (en) | 1994-03-26 | 1994-05-18 | Glaxo Spa | Chemical process |
| US5576470A (en) | 1994-08-29 | 1996-11-19 | Henkel Corporation | Polyol esters of ether carboxylic acids and fiber finishing methods |
| US5624920A (en) | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5633246A (en) | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5595997A (en) | 1994-12-30 | 1997-01-21 | Sepracor Inc. | Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine |
| WO1997016424A1 (en) | 1995-11-02 | 1997-05-09 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone |
| US5739321A (en) | 1996-05-31 | 1998-04-14 | Schering Corporation | 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones |
| EP0855396A1 (en) | 1997-01-22 | 1998-07-29 | ASTA Medica Aktiengesellschaft | Thioctic acid metabolites and methods of use thereof |
| WO1999042105A1 (en) | 1998-02-20 | 1999-08-26 | Avmax, Inc. | Epimorphian compound and its use |
| US6465490B1 (en) | 1999-07-16 | 2002-10-15 | Aventis Pharmaceuticals Inc. | Sulfuric acid mono-[3({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester |
| EP1225880A2 (en) | 1999-11-04 | 2002-07-31 | Andrx Corporation | Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders |
| AU2001240985B2 (en) | 2000-04-07 | 2005-08-04 | Pfizer Products Inc. | Estrogen agonist/antagonist metabolites |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
-
1994
- 1994-06-09 US US08/257,593 patent/US5631365A/en not_active Expired - Lifetime
- 1994-09-13 IL IL11095694A patent/IL110956A/en active Protection Beyond IP Right Term
- 1994-09-14 SG SG1996000732A patent/SG46208A1/en unknown
- 1994-09-14 EP EP94928563A patent/EP0720599B1/en not_active Expired - Lifetime
- 1994-09-14 DE DE2003199001 patent/DE10399001I2/de active Active
- 1994-09-14 ZA ZA947086A patent/ZA947086B/xx unknown
- 1994-09-14 DE DE69418613T patent/DE69418613T2/de not_active Expired - Lifetime
- 1994-09-14 CZ CZ1996839A patent/CZ288861B6/cs not_active IP Right Cessation
- 1994-09-14 WO PCT/US1994/010099 patent/WO1995008532A1/en active IP Right Grant
- 1994-09-14 KR KR1019960701555A patent/KR100186853B1/ko not_active IP Right Cessation
- 1994-09-14 PL PL94313589A patent/PL182617B1/pl unknown
- 1994-09-14 DK DK94928563T patent/DK0720599T3/da active
- 1994-09-14 JP JP7509799A patent/JP2803908B2/ja not_active Expired - Fee Related
- 1994-09-14 ES ES94928563T patent/ES2132432T3/es not_active Expired - Lifetime
- 1994-09-14 SK SK355-96A patent/SK281067B6/sk not_active IP Right Cessation
- 1994-09-14 MY MYPI94002445A patent/MY111314A/en unknown
- 1994-09-14 HU HU9600697A patent/HU221185B1/hu active Protection Beyond IP Right Term
- 1994-09-14 US US12/797,341 patent/USRE42461E1/en not_active Expired - Lifetime
- 1994-09-14 GE GEAP19946414A patent/GEP20043149B/en unknown
- 1994-09-14 NZ NZ274041A patent/NZ274041A/en not_active IP Right Cessation
- 1994-09-14 CA CA002172149A patent/CA2172149C/en not_active Expired - Lifetime
- 1994-09-14 AU AU77952/94A patent/AU681445C/en not_active Expired
- 1994-09-14 RU RU96110282A patent/RU2138480C1/ru active
- 1994-09-14 DE DE200412000026 patent/DE122004000026I2/de active Active
- 1994-09-14 CN CN94193466A patent/CN1050830C/zh not_active Expired - Lifetime
- 1994-09-14 UA UA96031081A patent/UA41948C2/uk unknown
- 1994-09-14 AT AT94928563T patent/ATE180249T1/de active
- 1994-09-14 TW TW083108481A patent/TW427974B/zh not_active IP Right Cessation
- 1994-09-15 TN TNTNSN94094A patent/TNSN94094A1/fr unknown
- 1994-09-15 MA MA23652A patent/MA23332A1/fr unknown
-
1996
- 1996-03-18 US US08/617,751 patent/US5767115A/en not_active Expired - Lifetime
- 1996-03-20 NO NO19961133A patent/NO305902B1/no not_active IP Right Cessation
- 1996-03-21 FI FI961300A patent/FI110321B/fi active Protection Beyond IP Right Term
-
1997
- 1997-03-06 BR BRPI1100159-3A patent/BR1100159A/pt unknown
- 1997-10-14 US US08/953,825 patent/US5846966A/en not_active Expired - Lifetime
-
1999
- 1999-05-27 GR GR990401399T patent/GR3030312T3/el unknown
-
2000
- 2000-04-19 CZ CZ20001415A patent/CZ288891B6/cs not_active IP Right Cessation
- 2000-06-15 US US09/594,996 patent/USRE37721E1/en not_active Ceased
-
2003
- 2003-07-31 NL NL300132C patent/NL300132I2/nl unknown
- 2003-08-21 NO NO2003007C patent/NO2003007I2/no unknown
- 2003-12-12 LU LU91050C patent/LU91050I2/fr unknown
-
2005
- 2005-02-01 NO NO2005003C patent/NO2005003I2/no unknown
- 2005-02-09 NL NL300172C patent/NL300172I2/nl unknown
- 2005-04-01 LU LU91160C patent/LU91160I2/fr unknown
- 2005-09-21 FR FR05C0040C patent/FR05C0040I2/fr active Active
-
2014
- 2014-09-10 NO NO2014022C patent/NO2014022I1/no unknown
- 2014-09-11 LU LU92544C patent/LU92544I2/xx unknown
- 2014-09-12 NO NO2014023C patent/NO2014023I1/no unknown
- 2014-09-12 LU LU92545C patent/LU92545I2/xx unknown
- 2014-09-12 BE BE2014C056C patent/BE2014C056I2/fr unknown
-
2017
- 2017-08-02 NO NO2017042C patent/NO2017042I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2132432T3 (es) | Compuestos de azetidinona hidroxi-sustituidos utiles como agentes hipocolesterolemicos. | |
| EA200100553A1 (ru) | Замещенные бициклические производные, полезные в качестве противораковых агентов | |
| EA200001146A1 (ru) | Производные изотиазола, применимые в качестве противораковых агентов | |
| DE69525479D1 (de) | 4-[(heterocycloalkyl-oder heteroaromatische)-substituiertes phenyl]-2-azetidinone zur verwendung als hypolipidemische agentien. | |
| FI955438A0 (fi) | N-asyylisulfamidihappoesterit (tai -tioesterit), N-asyylisulfonamidit ja N-sulfonyylikarbamiinihappoesterit (tai -tioesterit) hyperkolesteroleemisina aineina | |
| HUT72192A (en) | Compounds useful as sweeting agents, sweeting composition containing them and process for their preparation | |
| IL69175A (en) | 3,5-dimethyl-4-methoxy pyridyl-n-oxides,their preparation and their use as intermediates for the preparation of omeprazole derivatives | |
| ZA873978B (en) | Benzo(b)thiophene-and benzo(b)furancarboxamide derivatives,their preparation,and pharmaceutical compositions containing them | |
| DE69434888D1 (de) | 5-ht4-rezeptor-antagonisten | |
| MX9302957A (es) | Compuestos de xantina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
| AU575306B2 (en) | Proline derivatives | |
| ATE101611T1 (de) | Cephalosporine, mit an der stelle 3 einem substituierten vinylradikal, verfahren zu ihrer herstellung, ihre anwendung als medikamente, ihre sie enthaltenden praeparate und zwischenverbindungen. | |
| DE69524103D1 (de) | Fluorinierte 2-nitroimidazole analoge zur detektion von hypoxischen tumorzellen | |
| BR9911300A (pt) | Composto, composição farmacêutica, e, uso do composto | |
| GB9314758D0 (en) | Heterocyclic derivatives | |
| HU9203400D0 (en) | Method for producing new n-substituted n-nitroso-amino-aceto-nitryl derivatives and pharmaceutical derivatives containing them | |
| ZA84261B (en) | Bicyclo(4.2.0)1,3,5-octatriene derivatives,a process for their preparation and pharmaceutical compositions containing them | |
| ATE29251T1 (de) | Aminopyridincarbonsaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| IL115085A0 (en) | Bicyclic carboxamide derivatives their preparation and pharmaceutical compositions containing them | |
| KR920701232A (ko) | 신규 9α-히드록시-3-옥소-4,24(25)-스티그마스타디엔-26-산 유도체, 이의 제조법 및 이를 함유하는 약학 조성물 | |
| AU617849B2 (en) | New benzopyrrolidinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing them | |
| FI961423A0 (fi) | Antrasykliinidisakkaridit, menetelmä niiden valmistamiseksi sekä niitä sisältävät farmaseuttiset koostumukset | |
| ES2023760A6 (es) | Procedimiento para la preparacion de derivados benzotiazinicos. | |
| ATE6423T1 (de) | Bis-(substituierte phenoxyacetate) von n-alkyldialkanolaminen, verfahren zu ihrer bereitung, und diese enthaltende pharmazeutische zusammensetzungen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 720599 Country of ref document: ES |
|
| SPCF | Request for supplementary protection certificate filed |
Free format text: EZETIMIBA (EZETROL, VIEMM, ZIENT) Spc suppl protection certif: C200300018 Filing date: 20030701 |
|
| SPCG | Supplementary protection certificate granted |
Free format text: EZETIMIBA (EZETROL, VIEMM, ZIENT). Spc suppl protection certif: C200300018 Filing date: 20030701 Expiry date: 20171017 Effective date: 20040614 |
|
| SPCG | Supplementary protection certificate granted |
Free format text: PRODUCT NAME: EZETIMIBA+SIMVASTATINA(GOLTOR, INEGY, VYTORIN, ZEKLEN) Spc suppl protection certif: C200500011 Extension date: 20190402 Effective date: 20070521 |